12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PXT3003: Completed Phase II enrollment

Pharnext completed enrollment of 80 patients in a double-blind, placebo-controlled, French Phase II trial evaluating 3 doses...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >